The Nifty Index futures saw fall in open interest by 2.61% for the July series and rise in open interest by 5% for the August series. The September 2016 series which was introduced in the last week saw addition of 166% in open interest. Implied volatility on Nifty Options fell in the last week. Fall in volatility for options indicates support for Nifty at current levels.
Lupin Pharma has witnessed rise in turnover and open interest in the stock futures segment. The company announced that it has received notification that the inspection carried out by the United States Food & Drug Administration (USFDA) in July 2015 at its Goa facility has been completed and that the agency has issued Establishment Inspection Reports (EIR). Lupin, however, cautioned that the responses from the March 2016 USFDA inspection and updates thereafter are still under review by the USFDA.
A rise in turnover and open interest for the stock futures along with a rise in the stock price of Lupin Pharma suggests that the notifications are in favour of the Company and this would result in gaining clarity for the future growth. The news is positive for Lupin Pharma and the notification from the March 2016 inspection if in favour can trigger another set of rally for the stock.
Foreign Institutional Investors (FIIs) Derivative Statistics have shown rise in the open interest across Index Futures, Index Options, Stock Options and Stock Futures on a week on week basis.